Xenitra Locks in Exclusive China Deal for Biomiq Skincare Worth $5M
Xenitra secures exclusive Biomiq Skincare distribution rights across Greater China
Xenitra Limited (ASX: XEN) has entered a 4-year exclusive distribution agreement with Servatus Ltd, appointing Xenitra as exclusive distributor of Biomiq Skincare across Greater China. The agreement targets a minimum offtake of $5 million across the term, with a target commercial launch date of August 2026.
Biomiq Skincare becomes the second major brand to join Xenitra’s OPAL tokenised sales ecosystem, following the integration of EZZ in April 2026. The addition signals continued momentum in Xenitra’s strategy to build a multi-brand distribution platform in the region.
Agreement at a glance
- Distributor entity: M Best Tax Free Pty Limited (wholly owned subsidiary of Xenitra)
- Supplier: Servatus Ltd
- Territory: Greater China
- Term: 4-year Initial Term commencing 2 June 2026, auto-renewing in consecutive 3-year Renewal Terms
- Exclusivity: Exclusive distributor across all channels
- Target launch date: August 2026
- Minimum offtake thresholds: Year 1 — $0.5M / Year 2 — $1.0M / Year 3 — $1.5M / Year 4 — $2.0M
Director quote
Dr Anthony Noble, Non-Executive Chairman, Xenitra Limited
“I am very proud to see the Biomiq skincare range join Xenitra’s tokenised sales channel in China. This represents an exciting new line of products with significant commercial potential in the China market, treating the world’s eighth most prevalent condition, acne vulgaris and now also expanding with potent anti-aging formulas that have even greater potential in China, in line with the needs of an aging population. They are a natural fit for the tokenised sales channel having shown growth in the Australian market, very high customer repurchase rates and viral uptake via social media led ecommerce marketing.
“With sales in the first 6 weeks now approaching $1m, the real-world asset (RWA) tokenisation ecosystem is an exciting and now proven sales model. It creates a compelling opportunity to deepen engagement, strengthen loyalty and allows broad participation by customers and consumers. For international brands looking to enter the Asian market, the ecosystem provides the capacity for product authentication and full traceability which addresses key commercial concerns, while also providing a strong incentive for consumers to purchase and trial new products from premium brands through the loyalty and rewards program. Importantly, this sales channel is supported by established business fundamentals, including high-repurchase rate products, proven user networks across multiple markets, and recurring sales momentum within the product range on sale in the channel.”
When big ASX news breaks, our subscribers know first
What is the OPAL tokenised sales ecosystem and why does it matter?
Real-world asset (RWA) tokenisation in a retail context means that physical consumer goods transactions are recorded and verified on a blockchain, creating a permanent, tamper-proof record for every product moving through the supply chain. For consumer goods brands, this addresses one of the most commercially significant barriers to entry in China: counterfeiting and supply chain opacity.
Xenitra’s OPAL ecosystem is designed as a self-reinforcing commercial flywheel. Each transaction generates product authentication and full traceability data, while simultaneously feeding a loyalty and rewards programme that incentivises consumers to purchase and trial new products. The more brands and consumers participate, the stronger the network effects become.
For Western brands, the practical value is material. Verified provenance protects brand integrity, while the loyalty mechanics drive repeat purchase behaviour. The EZZ launch in April 2026 provided the first real-world deployment of the model, with sales approaching $1 million across the first 6 weeks. That result validates the commercial framework ahead of Biomiq’s planned entry into the ecosystem.
Biomiq Skincare — the product and the brand behind it
A science-backed skincare range targeting China’s highest-growth categories
Biomiq Skincare offers more than 20 SKUs across three core categories: acne treatment and prevention, minor skin conditions (including eczema, psoriasis, and skin irritation), and anti-ageing formulas designed specifically for the menopause and perimenopause skincare market. The breadth of the range positions it across several of China’s fastest-growing personal care segments.
The products are built on Servatus’s proprietary BioQx™ technology, which targets the microbiome-barrier-inflammation axis of skin health. Formulations incorporate functional microbial metabolites, barrier-supportive ceramides, and active anti-inflammatory botanical extracts. The underlying philosophy prioritises restoring biological balance rather than suppressing symptoms.
Biomiq is manufactured in Australia by Australian Biotherapeutics, a Servatus group company, at its production facility in Coolum, Queensland. Since launching commercially in 2022, the brand has recorded rapid sales growth in Australia from 2025, driven by social media-led ecommerce marketing and notably high customer repurchase rates. Those commercial signals, including viral uptake and repeat purchase behaviour, were identified as key indicators of suitability for the OPAL ecosystem.
As Dr Noble noted, acne vulgaris is “the world’s eighth most prevalent condition,” which provides meaningful market sizing context for the brand’s core category in China.
Minimum offtake schedule
| Agreement Year | Minimum Purchase Commitment | Cumulative Total |
|---|---|---|
| Year 1 | $0.5M | $0.5M |
| Year 2 | $1.0M | $1.5M |
| Year 3 | $1.5M | $3.0M |
| Year 4 | $2.0M | $5.0M |
If minimum purchase commitments are not met in any given year, Servatus may terminate the exclusive distribution rights for the products from the following contract year.
The next major ASX story will hit our subscribers first
Governance, outlook and what’s next for Xenitra
Related party disclosure handled at arm’s length
Dr Anthony Noble holds dual roles as Non-Executive Chairman of Xenitra and Executive Director of Servatus. In terms of his holdings, Dr Noble currently holds 40 million Xenitra options priced at $0.004, vesting upon achievement of $75 million in annual audited revenue and 2 consecutive cashflow-positive quarters being reported. He also holds 700,000 Servatus options priced at $0.15.
Dr Noble was absent from and did not vote on the approval of the Biomiq Agreement, and was not involved in the negotiation of its commercial terms. Independent directors assessed and approved the transaction on arm’s length terms, including Servatus’s capacity to supply the volume of products contracted for. Dr Noble receives no financial benefit from this agreement beyond his existing director fees from Xenitra and salary from Servatus, both of which are unaffected by the contract or sales under it.
Building the flywheel — what comes next
Xenitra now has two brands integrated or in active onboarding within the OPAL tokenised sales ecosystem. EZZ launched in April 2026, with Biomiq targeting a commercial launch in Greater China in August 2026. The OPAL ecosystem was designed from the outset to support multiple brands operating simultaneously, and the Biomiq agreement adds further weight to that capacity.
The escalating minimum offtake schedule, rising from $0.5M in Year 1 to $2.0M in Year 4, reflects growing revenue ambition across the agreement period. With the EZZ deployment now demonstrating real-world commercial traction, the near-term focus shifts to executing the Biomiq launch on schedule and establishing a second revenue stream within the tokenised channel.
Don’t Miss the Next Consumer Sector Breakout
Big News Blast delivers FREE breaking ASX announcements straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of the market on consumer, tech, healthcare, and more. Hit the “Free Alerts” button to start receiving real-time coverage the moment news breaks.